Celltrion generates W688.7b in operating cash in H1, eyes record annual targets

Celltrion has extended its record-breaking earnings streak into the first half of this year, demonstrating robust cash generation on the back of its fully integrated biopharmaceutical business spanning drug development, production, distribution and sales. The company has built a stable cash-generation base by expanding its presence in global markets, and is reinforcing a virtuous cycle in which that cash funds future growth investment and shareholder returns.

Having posted record earnings in the first half, Celltrion plans to sustain strong growth momentum in the second half and is committed to surpassing its full-year targets of 5.3 trillion won ($3.83 billion) in sales and 1.8 trillion won in operating profit.

Celltrion generated 688.7 billion won in cash from operations in the first half of this year, up 34 percent from 514 billion won in the same period last year. Operating cash flow after corporate tax payments came to 651.4 billion won, more than doubling year-on-year and underscoring the company's strong cash-generation capacity. Celltrion also recorded 1.09 trillion won in operating cash for the full year last year, reflecting a sustained track record of healthy cash generation.

Cash generated from operations is a key indicator of a company's fundamentals, as it shows how much of its business activity translates into actual cash inflows.

Alongside this cash-generation strength, Celltrion has maintained a stable financial structure. As of the second quarter, the company held 1.2 trillion won in cash and cash equivalents, providing a solid foundation for research and development, strategic investment and shareholder return initiatives. Its debt-to-equity ratio stood at 31.3 percent — well below the 65 percent average for large domestic conglomerates — indicating that the company's growth has been driven by substance rather than mere scale expansion.

Celltrion's strong cash generation is largely attributed to the rapid market expansion of its high-margin new products. In the first half of this year, the company posted sales of 2.54 trillion won and operating profit of 773.7 billion won, up 40.8 percent and 97.4 percent, respectively, from the same period last year. The double-digit growth comes after Celltrion set all-time records in 2025 with full-year sales of 4.16 trillion won and operating profit of 1.17 trillion won, making the first-half performance all the more encouraging.

Established products such as Remsima and Truxima continued to deliver steady sales, while the new product lineup — including Remsima SC, Yuflyma, Vegzelma, Steqeyma, Omlyclo, Idenzelt, Stoboclo, Osenvelt and Aptozma — recorded combined first-half sales of 1.41 trillion won, surging 72.5 percent year-on-year.

Having achieved record results even in the seasonally slower first half, Celltrion plans to sustain high growth in the second half by supplying major government tender volumes and expanding the number of markets and market share for its new products.

Going forward, Celltrion plans to continuously reinvest the stable cash generated from its biosimilar business into future growth drivers — including next-generation biosimilars, drug development and production facility expansion — to enhance long-term corporate value.

Through these efforts, the company aims to build a portfolio of 18 biosimilars by 2030 and advance its new drug pipeline in areas such as antibody-drug conjugates, multispecific antibodies and obesity treatments. To get ahead of rising global biopharmaceutical demand, Celltrion has already secured production capacity of 250,000 liters at its Incheon Songdo facility and 66,000 liters at its Branchburg, New Jersey plant, and plans to further strengthen its manufacturing capabilities.

Celltrion has also been stepping up its shareholder return policy to share the fruits of its growth. The company recently established a principle of allocating one-third — about 33 percent — of its annual consolidated net profit for the period to shareholder returns. Its strategy is to build a virtuous cycle of earnings growth and shareholder value enhancement through a combination of cash dividends and share buyback and cancellation.

"We are pursuing a balanced approach to future growth investment and shareholder returns, underpinned by the growth of our high-margin new products and our stable cash-generation capacity," a Celltrion official said. "Having announced our commitment to directing a portion of net profit toward shareholder returns, we will continue to do our best to grow alongside our investors."